CD274 and neoplasm: Our data showed that dual-targeted CAR-T cells also responded to “by-standing” PD-L1-expressing host cells when they are simultaneously triggered by the cognate antigen expressed on tumor cells, indicating the great potential of the PD-L1 CCR in clinical applications, especially in contexts with PD-L1− tumor cells but PD-L1-enriched TME-associated non-tumor cells [23, 24].